

温州康

2 PRINCIPAL FINANCIAL DATA AND INDICATORS

	For the six months ended June 30,	
	2017	2016
	RMB'000	*RMB'000*
	(Unaudited)	*(Unaudited)*
	283,136	189,680
	42,319	36,818
	(12,014)	(10,531)
	30,305	26,287
	31,710	28,208
	(1,405)	(1,921)

	As of June 30,	As of December 31,
	2017	2016
	(RMB'000)	*(RMB'000)*
	(Unaudited)	*(Audited)*

	For the six months ended June 30,	
	2017	2016
Total average outpatient spending per visit (RMB)	**524**	512
Total treatment and general healthcare services revenue (RMB'000)	**166,226**	129,416
Total pharmaceutical sales revenue (RMB'000)	**60,303**	49,563

B187.0 30.1% 2016, 27.9% - 1.6% 82.5% 30, 2016: 80.3%).

B39.5 12.2% 2016, 10.2% ( ) 2.3%. 17.5% (30, 2016: 19.7%),

	For the six months ended June 30,	
	2017	2016
	(RMB'000)	*(RMB'000)*
	(Unaudited)	*(Unaudited)*
	58,173	48,086
	50,903	39,834
	9,857	4,785
	13,642	7,103
	8,120	6,544
	4,182	2,180
	6,756	6,094
Cost of revenue for owned hospitals	**151,633**	114,626

B151.6 32.3% 2016, 21.0% ; ( ) 27.8% ; ( ) B11.6 A, 2016, 97.7%.

38.4% (30, 2016: 42.0%). 33.6% (30, 2016: 34.8%). 15.5% (30, 2016: 10.4%). 2016.

4.1.2 Gross Profit and Gross Profit Margin

[illegible] B92.0 [illegible] 31.2% [illegible] 2016. [illegible] B81.6 [illegible] B8.12%, [illegible] 8.1.7 ( ) ( ) ( ) ( ) (.)

4.1.5 Administrative Expenses

4.1.6 Finance (Expe.

4.1.7 Investment Income/(Loss)

	For the six months ended June 30,	
	2017	2016
	(RMB'000)	*(RMB'000)*
	(Unaudited)	*(Unaudited)*
	(2,852)	(2,200)
	5,243	
	2,391	(2,200)

RMB2.4 (30, 2016: RMB2.2), 49.0% 32.7% RMB5.2 16.3%

4.1.8 [illegible]

4.2 Financial Position

4.2.1 Inventory

A [illegible] 30, 2017, [illegible] $176.6 [illegible] ([illegible] 31, 2016: $162.8 [illegible]), [illegible] ( ) [illegible]

125 (30, 2016: 120).

4.2.3 Other Receivables and Prepayments

A 30, 2017, B75.8 (31, 2016: B77.0).

4.2.4 Investment Properties

A 30, 2017, B72.2 (31, 2016: B72.2), (3 & 4) :

B (3 & 4)

A

	(2012) 3-290617, (2012) 3-290604, (2012) 3-290602, (2012) 3-290616, (2012) 3-290595, (2012) 3-290606, (2012) 3-290593 (2012) 3-290607
	75%
(A)	3,722.29
(A) ( )	12,854.06
	-
	50 (29, 2053),

4.3.1 Net Cash Generated from Operating Activities

A 30, 2017, B3.5 B30.3 B20.9 B58.3 B33.6

4.3.2 Net Cash Used in Investing Activities

B134.7 B158.1 B37.9

4.3.3 Net Cash Generated from Financing Activities

B61.8 B90.0 B37.7

4.3.4 Significant Investment, Acquisition and Disposal

30, 2017.

4.4 Indebtedness

4.4.1 Bank Borrowings

A 30, 2017, B269.0 (31, 2016: B216.7), B90.0 B37.7

4.4.2 Contingent Liabilities

A 30, 2017,

4.4.8 Employees and Remuneration Policy

A 30, 2017, 1,589 - (31, 2016: 1,348 -). ( ) 71.3 (30, 2016: 55.7). 97.1 ( ).

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

6 REVIEW OF INTERIM RESULTS

A 30, 2017

A (A) . ( ) 0.313 0

9.2 Consolidated Interim Financial Information

9.2.1 Interim Consolidated Statement of Comprehensive Income

		Six months ended 30 June,	
		2017	2016
		RMB	
		(Unaudited)	
1.	**Revenue**	**283,136,307**	189,680,305
		(191,153,046)	(119,578,600)
		(3,937,078)	(34,107)
		(445,240)	(1,017,758)
		(39,814,343)	(36,359,241)
		(10,436,551)	9,785,791
		(2,823,150)	(1,188,953)
		2,390,872	(2,199,509)
		(2,852,505)	(2,199,509)
		2,692,900	
2.	**Operating profit**	**39,610,671**	39,087,928
		5,377,451	184,815
		(2,668,911)	(2,454,270)
		(95,691)	(84,100)
3.	**Total profit**	**42,319,211**	36,818,473
		(12,013,726)	(10,531,210)

	Six months ended 30 June,	
	2017	2016
	RMB	*RMB*
	(Unaudited)	*(Unaudited)*
4. Net profit	**30,305,485**	26,287,263

LIABILITIES AND OWNERS' EQUITY	30 June 2017	31 2016
Current liabilities		
[illegible]	**120,000,000**	30,000,000
A [illegible]	**80,476,871**	43,271,014
A [illegible]	**60,655,362**	71,147,900
[illegible]	**15,316,095**	19,552,350
[illegible]	**27,168,560**	41,195,655
[illegible]	**87,816,113**	38,922,694
[illegible]	**18,260,000**	
[illegible]	**17,480,304**	54,180,304
Total current liabilities	**427,173,305**	298,269,917
Non-current liabilities		
[illegible]	**148,950,190**	149,950,190
[illegible]	**89,463,200**	86,738,600
[illegible]	**10,632,800**	10,632,800
[illegible]	**13,444,342**	16,420,433
Total non-current liabilities	**262,490,532**	263,742,023
Total liabilities	**689,663,837**	562,011,940
Owners' equity		
[illegible]	**73,040,000**	73,040,000
[illegible]	**795,919,512**	795,604,861
[illegible]	**18,548,942**	18,548,942
[illegible]	**134,640,863**	121,190,550
Total equity attributable to owners of the parent company	**1,022,149,317**	1,008,384,353
[illegible]	**45,572,551**	32,985,630
Total owners' equity	**1,067,721,868**	1,041,369,983
TOTAL LIABILITIES AND OWNERS' EQUITY	**1,757,385,705**	1,603,381,923

	For the six months ended 30 June,	
	2017	2016
	RMB	*RMB*
	(Unaudited)	*(Audited)*
3. Cash flows from financing activities		
[illegible]	**14,100,000**	2,400,000
[illegible]	**14,100,000**	2,400,000

9.2.4 Interim Consolidated Statement of Changes In Equity

	Equity attributable to owners of the parent company					
	Share capital	Capital surplus	Surplus reserve	Retained earnings	Non-controlling interests	Total owners' equity
Balance at 1 January 2017	73,040,000	795,604,861	18,548,942	121,190,550	32,985,630	1,041,369,983
[illegible]	—	—	—	31,710,313	(1,404,828)	30,305,485
[illegible]	—	—	—	—	14,100,000	14,100,000
[illegible]	—	206,400	—	—	—	206,400
[illegible]	—	108,251	—	—	(108,251)	—
[illegible]	—	—	—	(18,260,000)	—	(18,260,000)
Balance at 30 June 2017	73,040,000	795,919,512	18,548,942	134,640,863	45,572,551	1,067,721,868

	Equity attributable to owners of the parent company					
	Share capital	Capital surplus	Surplus reserve	Retained earnings	Non-controlling interests	Total ownersw

9.3 Notes to the Consolidated Interim Financial Information prepared in accordance with the Accounting Standard for Business Enterprises of the PRC

9.3.3 Revenue and cost of sales

	Six months ended 30 June	
	2017	2016
	RMB	*RMB*
	(Unaudited)	*(Unaudited)*
[illegible]	**238,108,930**	187,817,343
[illegible]	**45,027,377**	1,862,962
	283,136,307	189,680,305
[illegible]	**156,885,868**	118,945,305
[illegible]	**34,267,178**	
	191,153,046	118,945,305

Revenue and cost of sale from main operations

	Six months ended 30 June 2017	
	RMB	***RMB***
	(Unaudited)	***(Unaudited)***
Revenue from main		

	30	2016
	B	B
	( )	( )
	49,563,165	40,834,453
	129,416,332	73,791,802
	8,837,846	4,319,050
	187,817,343	118,945,305

9.3.4 Earnings per share

( ) B

	Six months ended 30 June,	
	2017	2016
	RMB	*B*
	(Unaudited)	*( )*
	31,710,313	28,208,189
W	**73,040,000**	73,040,000
B	**0.43**	0.39

( )

30 2017. A

9.3.5 Income tax expenses

	Six months ended 30 June,	
	2017	2016
	RMB	*RMB*
	(Unaudited)	*(Unaudited)*
	14,743,399	13,915,240
	(2,729,673)	(3,384,030)
	12,013,726	10,531,210

	Six months ended 30 June,	
	2017	2016
	RMB	*RMB*
	(Unaudited)	*(Unaudited)*
	42,319,2114	36,818,473
25%	**10,579,803**	9,204,618

9.3.6 Dividends

24, 2017, B RMB18,260,000
31, 2016 73,040,000
31, 2016. A
30, 2017.

24, 2016, B RMB18,260,000
31, 2015. 2015
14, 2016 14, 2016.

10 DEFINITIONS

A –	2016 14, 2017
A –	B
B –	B (北京怡寧醫院有限公司), 17, 2015 32.67%
B – B –	
–	(蒼南康寧醫院有限公司), 15, 2012,
–	(成都仁一醫院有限公司), 29, 2010 (成都濟宏醫院有限公司) 28, 2015
–	(重慶合川康寧醫院有限公司), 5, 2015 40%

(淳安黃鋒康恩醫院)

: 2120)

14

(溫州怡寧老年醫院有限公司),

□□□